Amgen
Executive Summary
Product tampering resulted in contents from eight vials of Epogen (epoetin alfa) and Neupogen (filgrastim) 300 mcg being extracted and the vials refilled with a replacement solution, the company said in a Feb. 13 "Dear Healthcare Provider" letter. "Although the replacement solution has thus far been shown to be non-toxic, the sterility of these vials was compromised," therefore posing a safety risk, especially for immune compromised patients, the letter states